The role of nitric oxide in neurodegeneration: Potential for pharmacological intervention

Drugs and Aging

Volumn 12, Issue 4, 1998, Pages 251-259

  Molina, José Antonio ^a,c   Jiménez Jiménez, Félix Javier ^b   Ortí Pareja, Miguel ^a   Navarro, José Antonio ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; HUNTINGTON CHOREA; MEMORY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ENZYME INHIBITORS; HUMANS; NEURODEGENERATIVE DISEASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATION-REDUCTION;

EID: 0031941816     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812040-00001     Document Type: Article

References (122)

1. Koshland Jr DE. The molecule of the year [editorial]. Science 1992; 258: 1861-3
2. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6
3. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42
5. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12
6. Harald HH, Schmidt W, Walter U. NO at work. Cell 1994; 78: 919-25
7. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 1992; 32: 297-311
8. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-902
9. Greenberg DA. Nitric oxide. In: Collins RA, editor. Neurochemistry of cell death. Course #146, 45th Annual Meeting of the American Academy of Neurology; 1993: 21-7
10. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994; 63: 175-95
11. Nathan C, Xie Q. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78: 915-8
12. Oset-Gasque MJ, Parramón M, Hortelano S, et al. Nitric oxide implication in the control of neurosecretion by chromaffin cells. J Neurochem 1994; 63: 1693-700
13. Lipton SA, Chol YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364: 626-32
14. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994; 78: 931-6
15. Snyder SH. Janus face of nitric oxide [letter]. Nature 1993; 364: 577
16. Bonfoco E, Kraine D, Ankarcrona M, et al. Apoptosis and neurosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995; 92: 7162-6
17. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite (ONOO ) reacts with superoxide dismutase to give reactive nitronium ion [abstract]. Free Radic Biol Med 1990; 9 Suppl. 1: 131
18. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide-dismutase. Arch Biochem Biophys 1992; 298: 431-7
19. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993; 268: 12231-4
20. Molina JA, Navarro JA, Benito-Leon J, et al. Oxido nitrico. In: Luquin MR, Jiménez-Jiménez FJ, Martínez-Vila E, et al., editors. Mecanismos de muerte neuronal y neuroprotección en enfermedades neurológicas. Neurología (Spain) 1996; 11 Suppl. 3: 46-53
21. Resink A, Dawson VL, Dawson TM. Nitric oxide synthase inhibitors: future therapies for CNS disorders? CNS Drugs 1996; 6: 351-7
22. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthetase indicating a neural role for nitric oxide. Nature 1990; 347: 768-70
23. Togashi H, Sasaki M, Frohman E, et al. Neuronal (type I) nitric oxide synthase regulates nuclear factor kB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci U S A 1997; 94: 2676-80
24. Dinnerman JL, Dawson TM, Schell MJ, et al. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci U S A 1994; 91: 4214-8
25. Bredt DS, Glatt CE, Hwang PM, et al. Nitric oxide synthase-protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH-diaphorase. Neuron 1991; 7: 615-24
26. Hope BT, Michael GJ, Knigge KM, et al. Neuronal NADPH-diaphorase is a nitric oxide synthetase. Proc Natl Acad Sci U S A 1991; 88: 2811-4
27. Dawson TM, Bredt DS, Fotuhi M, et al. Nitric oxide synthetase and neuronal NADPH-diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci U S A 1991; 88: 7797-801
28. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995; 57: 683-706
29. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995; 57: 737-69
30. Suárez-Pinzón WL, Strynadka K, Schultz R, et al. Mechanism of cytokine-induced destruction of rat insulinoma cells: the role of nitric oxide. Endocrinology 1994; 134: 1006-10
31. Wink DA, Kasprzak KS, Maragos CH, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991; 254: 1001-3
32. Zhang J, Dawson VL, Dawson TM, et al. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 1994; 263: 687-9
33. de Murcia G, Menisser-de Murcia J, Schreiber V. Poly(ADP-ribose) polymerase: molecular biological aspects. Bioessays 1991; 13: 455-62
34. Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990; 283: 537-41
35. Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994; 78: 927-30
36. Cleeter MV, Cooper JM, Darley-Usmar VM, et al. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative diseases. FEBS Lett 1994; 345: 50-4
37. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. Ann Neurol 1992; 32: 297-311
38. Zhang J, Snyder SH. Nitric oxide stimulates auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci U S A 1992; 89: 9382-5
39. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336: 385-8
40. Knowles RG, Palacios M, Palmer RMJ, et al. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of soluble guanylate cyclase. Proc Natl Acad Sci U S A 1989; 86: 5159-62
41. Garthwaite J. Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci 1991; 14: 60-7
42. Garthwaite J, Southam E, Anderton MA. Kainate receptor linked to NO synthesis from arginine. J Neurochem 1989; 53: 1952-4
43. Marin P, Quignard JF, Lafon-Cazal M, et al. Non-classical glutamate receptor, blocked by both NMDA and non-NMDA antagonists, stimulate nitric oxide production in neurons. Neuropharmacology 1993; 32: 29-36
44. Hu J, El-Fakahany EE. Role of intercellular and intracellular communication by nitric oxide in coupling of muscarinic receptors to activation of guanylate cyclase in neuronal cells. J Neurochem 1993; 61: 578-85
45. Chaki S, Inagami T. New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesis. Mol Pharmacol 1993; 43: 603-8
46. Zarhan ED, Ye X, Ades AM, et al. Angiotensin-induced cyclic GMP production is mediated by multiple receptor subtypes and nitric oxide in NIE-115 neuroblastoma cells. J Neurochem 1992; 58: 1960-3
47. Reiser G. Mechanism of stimulation of cyclic-GMP level in a neuronal cell line mediated by serotonin (5-HT3) receptors. Eur J Biochem 1990; 189: 547-52
48. Fostermann U, Gorsky LD, Pollock JS, et al. Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in NIE-15 neuroblastoma cells requires calcium and calmodulin. Mol Pharmacol 1990; 101: 722-6
49. ++ ionophore raise cyclic GMP levels in a neuronal cell line via formation of nitric oxide. Br J Pharmacol 1990; 38: 7-13
50. Shibuki K, Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature 1991; 349: 326-8
51. Bohme GA, Bon C, Stulzmann JM, et al. Possible involvement of nitric oxide in long-term potentiation. Eur J Pharmacol 1991; 199: 379-81
52. O'Dell TJ, Hawkins RD, Kandel ER, et al. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci U S A 1991; 199: 11285-9
53. Schuman EE, Madison DW. A requirement for the intercellular messenger nitric-oxide in long-term potentiation. Science 1991; 254: 1503-6
54. Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Shaffer collateral-commissural pathway of the rat hippocampus. J Physiol Lond 1983; 334: 33-46
55. Chapman PF, Atkins CM, Allen MT, et al. Inhibition of nitric oxide synthesis impairs two different forms of learning. Neuroreport 1992; 3: 567-70
56. Venturini CM, Knowles RG, Palmer RMJ, et al. Synthesis of nitric oxide in the bovine retina. Biochem Biophys Res Commun 1991; 180: 920-5
57. Morley JE, Flood JF. Evidence that nitric oxide modulates food intake in mice. Life Sci 1991; 49: 707-11
58. Moore PK, Oluyomi AO, Babbedge RC, et al. L-N-nitro-arginine-methyl-ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 1991; 102: 198-202
59. Breer H, Shepherd GM. Implications of NO/cGMP system in olfaction. Trends Neurosci 1993; 16: 5-9
60. Murphy S, Simmons ML, Agullo L, et al. Synthesis of nitric oxide in CNS glial cells. Trends Neurosci 1993; 16: 323-8
61. Agullo L, García A. Characterization of noradrenaline-stimulated cyclic GMP formation in brain astrocytes in culture. Biochem J 1992; 288: 619-24
62. Agullo L, García A. Different receptors mediate stimulation of nitric oxide-dependent cyclic GMP formation in neurons and astrocytes in culture. Biochem Biophys Res Commun 1992; 182: 1362-8
63. Murphy S, Minor RL, Welk G, et al. Evidence for an astrocyte-derived vasorelaxing factor with properties similar to nitric oxide. J Neurochem 1990; 55: 349-51
64. Murphy S, Minor RL, Welk G, et al. Central nervous system astroglial cells release nitrogen oxide(s) with vasorelaxant properties. J Cardiovasc Pharmacol 1991; 7 Suppl 3: S265-8
65. Galea E, Reis DJ, Feinstein DL. Cloning and expression of rat astroglial inducible nitric oxide synthase [abstract]. Soc Neurosci Abst 1993; 19: 1121
66. Wallace MN, Fredens K. Activated astrocytes of the mouse hippocampus contain high levels of NADPH-diaphorase. Neuroreport 1992; 3: 953-6
67. Endoch M, Maiese K, Pusinelli WA, et al. Reactive astrocytes express NADPH-diaphorase in vivo after transient ischemia. Neurosci Lett 1993; 154: 125-8
68. Mine-Golomb D, Schwartz JP. Transcription of the brain oxide nitric synthase gene in neural cell cultures [abstract]. Soc Neurosci Abst 1992; 18: 1004
69. Aoki E, Sembra R, Mikosshiba K, et al. Predominant localization in glial cells of free L-arginine: immunocytochemical evidence. Brain Res 1991; 547: 190-2
70. Manzoni O, Prezeau L, Marin P, et al. Nitric oxide-induced blockade of NMDA receptors. Neurology 1992; 8: 653-62
71. Wink DA, Hanbauer I, Krishna MC, et al. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci U S A 1992; 90: 9813-7
72. Wink DA, Hanbauer I, Grisham MB, et al. Chemical biology of nitric oxide: regulation and protective and toxic mechanism. Curr Top Cell Regul 1996; 34: 159-87
73. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of local ischemia. Stroke 1997; 28: 1283-8
74. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-12
75. Youdim MBH, Ben-Sachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993; 8: 1-12
76. Youdim MBH, Ben-Sachar D, Eshel G, et al. The neurotoxicity of iron and nitric oxide, relevance to the etiology of Parkinson's disease. Adv Neurol 1993; 60: 259-66
77. Bret DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A 1989; 86: 5159-62
78. McCall T, Vallance P. Nitric oxide takes center stage with newly defined roles. Trends Pharmacol Sci 1991; 13: 1-6
79. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 523-7
80. Slater M, Duffy C, Garthwhite J, et al. Ex vivo measurement of brain tissue nitrite and nitrate accurately reflects nitric oxide synthase in vivo. J Neurochem 1996; 66: 1683-90
81. Ikeda M, Sato I, Yuasa T, et al. Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic disease. J Neural Transm Gen Sect 1995; 100: 263-7
82. Molina JA, Jiménez-Jiménez FJ, Navarro JA, et al. Cerebrospinal fluid nitrate levels in patients with Parkinson's disease. Acta Neurol Scand 1996; 93: 123-6
83. Kuiper MA, Visser JJ, Bergsman PL, et al. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease. Alzheimer's disease and multiple system atrophy patients. J Neurol Sci 1994; 121: 46-9
84. Qureshi GA, Baigh S, Bednar I, et al. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 1995; 6: 1642-4
85. Bockelmann R, Wolf G, Ransmayr G, et al. NADPH-diaphorase/nitric oxide containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect 1994; 7: 115-21
86. Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996; 72: 355-63
87. Gatto EM, Carreras MC, Pargament GA, et al. Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease. Mov Disord 1996; 11: 261-7
88. Schulz JB, Matthews RT, Muqit MM, et al. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64: 936-9
89. Przedborski S, Jackson-Lewis V, Yokohama K, et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996; 93: 4565-71
90. Hantraye P, Brouillet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Med 1996; 2: 1017-21
91. Smith TS, Swerdlow RH, Parker Jr WD, et al. Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994; 5: 2598-600
92. Di Monte DA, Royland JE, Jakowec MW, et al. Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase. J Neurochem 1996; 67: 2443-50
93. Kish SJ, Bergeron C, Rajput A, et al. Brain cytochromic oxidase in Alzheimer's disease. J Neurochem 1992; 59: 776-9
94. Parker WD, Parks JK, Filley CM, et al. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994; 44: 1090-6
95. Mutisya EM, Bowling AC, Beal ME. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994; 63: 2179-84
96. Rossi F, Bianchini E. Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem Biophys Res Commun 1996; 225: 474-8
97. Meda L, Cassatella MA, Szendri GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995; 374: 647-50
98. Vodovotz Y, Lucia MS, Flanders KC, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996; 184: 1425-33
99. Good PF, Werner P, Hsu A, et al. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996; 149: 21-8
100. Milstien S, Sakai N, Brew BJ, et al. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J Neurochem 1994; 63: 1178-80
101. Navarro JA, Molina JA, Jiménez-Jiménez FJ, et al. Cerebrospinal fluid nitrate levels in patients with Alzheimer's disease. Acta Neurol Scand 1996; 94: 411-4
102. Rebeck GW, Marzloff K, Hyman BT. The pattern of NADPH-diaphorase staining, a marker of nitric oxide synthase activity, is altered in the perforant pathway terminal zone in Alzheimer's disease. Neurosci Lett 1993; 152: 165-8
103. Norris PJ, Faull RL, Emson PC. Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains. Brain Res Mol Brain Res 1996; 41: 36-49
104. Hyman BT, Marzloff K, Wenniger JJ, et al. Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Ann Neurol 1992; 32: 818-20
105. Bonkale WL, Winblad B, Ravid R, et al. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci Lett 1995; 187: 5-8
106. Dorheim MA, Tracey WR, Pollock JS, et al. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem Biophys Res Commun 1994; 205: 659-65
107. Lockhart BP, Benicourt C, Junien JL, et al. Inhibitors of free radical formation fail to attenuate direct beta-amyloid 25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res 1994; 39: 494-505
108. Chou SM, Wang HS, Komai K. Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: an immunohistochemical study. J Chem Neuroanal 1996; 10: 249-58
109. Chou SM, Wang HS, Taniguchi A. Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. J Neurol Sci 1996; 134 Suppl.: 16-26
110. Kuljis RO, Schelper RL. Alterations in nitrogen monoxide-synthesizing cortical neurons in amyotrophic lateral sclerosis with dementia. J Neuropathol Exp Neurol 1996; 55: 25-35
111. Norris PJ, Waldvogel JH, Faull RL, et al. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum on Huntington disease. Neuroscience 1996; 72: 1037-47
112. Li XJ, Sharp AH, Li SH, et al. Huntington-associated protein (HAPI): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc Natl Acad Sci U S A 1996; 93: 4839-44
113. Ferrante RJ, Kowall NW, Beal MF, et al. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985; 30: 561-3
114. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992; 89: 3686-90
115. Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FK 506 complexes. Cell 1991; 66: 807-15
116. Worrall NK, Misko TP, Sullivan PM, et al. Corticosteroids inhibit expression of inducible nitric oxide synthase during acute cardiac allograft rejection. Transplantation 1996; 61: 324-8
117. Minghetti L, Nicolini A, Polazzi E, et al. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997; 19: 152-60
118. Hecker M, Preiss C, Klemm P, et al. Inhibition by antioxidants of nitric oxide synthase expression in murine macrophages: role of nuclear factor kappa B and interferon regulatory factor I. Br J Pharmacol 1996; 118: 2178-84
119. Skaper SD, Facci L, Schiavo N, et al. Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GMI: implications for Parkinson's disease. J Pharmacol Exp Ther 1992; 263: 1440-6
120. Janson AM, Agnati LF, Fuxe K, et al. GMI ganglioside protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988; 132: 587-8
121. Herrero MT, Kastner A, Pérez-Otano I, et al. Gangliosides and parkinsonism. Neurology 1993; 43: 2132-4
122. Dawson TM, Hung K, Dawson VL, et al. Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Ann Neurol 1995; 37: 115-8